Bicycle Therapeutics Reports Material Agreement and Officer Changes
Ticker: BCYC · Form: 8-K · Filed: Apr 18, 2024 · CIK: 1761612
Sentiment: neutral
Topics: material-agreement, management-change, corporate-governance
Related Tickers: BCYC
TL;DR
Bicycle Therapeutics inked a new deal and shuffled some execs/directors on April 16th.
AI Summary
On April 16, 2024, Bicycle Therapeutics plc entered into a material definitive agreement. The company also reported the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with compensatory arrangements for these officers. The filing includes financial statements and exhibits related to these events.
Why It Matters
This filing indicates significant corporate actions, including new agreements and changes in leadership, which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with new material agreements, can introduce uncertainty and potential shifts in strategy.
Key Players & Entities
- Bicycle Therapeutics plc (company) — Registrant
- April 16, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Bicycle Therapeutics plc?
The filing does not specify the details of the material definitive agreement, only that one was entered into on April 16, 2024.
Who are the directors or officers that have departed from Bicycle Therapeutics plc?
The filing mentions the departure of directors or certain officers but does not name the specific individuals involved.
Who has been elected as a director or appointed as an officer of Bicycle Therapeutics plc?
The filing indicates the election of directors and appointment of certain officers, but does not provide their names.
What are the compensatory arrangements for the newly appointed officers?
The filing notes that compensatory arrangements for certain officers are part of the reported events, but the specifics are not detailed in this summary.
What financial statements and exhibits are included with this 8-K filing?
The filing states that financial statements and exhibits are included, but their specific content is not detailed in the provided text.
Filing Stats: 1,636 words · 7 min read · ~5 pages · Grade level 11.3 · Accepted 2024-04-18 07:00:28
Key Financial Figures
- $21.25 — er share, at a public offering price of $21.25 per non-voting ordinary share to the BB
- $100 million — nds for gross proceeds of approximately $100 million. The offering resulted in net proceeds
- $215.1 million — ulted in net proceeds to the Company of $215.1 million. The BBA Funds hold more than 10% of th
Filing Documents
- tm2412008d1_8k.htm (8-K) — 44KB
- tm2412008d1_ex10-1.htm (EX-10.1) — 23KB
- tm2412008d1_ex10-2.htm (EX-10.2) — 95KB
- 0001104659-24-048576.txt ( ) — 411KB
- bcyc-20240416.xsd (EX-101.SCH) — 3KB
- bcyc-20240416_def.xml (EX-101.DEF) — 26KB
- bcyc-20240416_lab.xml (EX-101.LAB) — 36KB
- bcyc-20240416_pre.xml (EX-101.PRE) — 25KB
- tm2412008d1_8k_htm.xml (XML) — 6KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On April 18, 2024, Bicycle Therapeutics plc (the " Company ") entered into a registration rights agreement (the " Affiliate Registration Rights Agreement ") with 667, L.P. and Baker Brothers Life Sciences, L.P. (collectively, the " BBA Funds "), as described below under the heading "Affiliate Registration Rights Agreement" in Item 5.02 and incorporated herein by reference.
02 Departure of Directors or Certain Officers;
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Veronica Jordan, Ph.D. On April 16, 2024, Veronica Jordan, Ph.D. notified the Board of Directors of the Company (the " Board ") of her decision to resign as a Class I director of the Company and as the Chair of the Compensation Committee of the Board and as a member of the Audit Committee of the Board, effective as of the close of business on April 17, 2024, New York City time. Dr. Jordan's decision to resign from the Board was not the result of any disagreement between Dr. Jordan and the Company, its management, the Board or any committees thereof on any matter relating to the Company's operations, policies or practices. Dr. Jordan will continue to serve the Company as a consultant pursuant to a consulting agreement (the " Consulting Agreement "). The initial term of the Consulting Agreement will be two years , provided that the term will automatically renew in one-year increments unless a notice of termination has been provided by either party. Dr. Jordan will receive compensation of GBP 12,000 or equivalent in local currency per year and any outstanding equity awards held by Dr. Jordan will continue to vest in accordance with their terms, subject to Dr. Jordan continuing to comply with the terms of the Consulting Agreement through each applicable vesting date. The foregoing description of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Agreement, which is filed herewith as Exhibit 10.1 and is incorporated herein by reference. Appointment of Felix J. Baker, Ph.D. On April 16, 2024, the Board , upon the recommendation of the Nominating and Corporate Governance Committee of the Company (the " NCGC "), appointed Felix J. Baker, Ph.D. to the Board, effective as of April 18, 2024, New York City time. Dr.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Consulting Agreement, dated April 17, 2024, by and between the Company and Veronica Jordan 10.2 Registration Rights Agreement, dated April 18, 2024, by and among the Company and 667, L.P. and Baker Brothers Life Sciences, L.P. 104 Cover Page Interactive Data File (formatted in Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 18, 2024 BICYCLE THERAPEUTICS PLC By: /s/ Alethia Young Name: Alethia Young Title: Chief Financial Officer